@gaabfernandes's peptide safety claims, fact-checked

What does this Instagram post actually claim?

Gabriela Fernandes pushes back against peptide safety concerns, arguing that peptides like GHK-Cu and ipamorelin aren't "new" or dangerous. She suggests these treatments have years of research behind them and are already used outside Brazil. Her post implies that regulatory approval is just a matter of time, not safety.

The video shows her organizing peptide vials with colorful caps while dismissing critics. She uses hashtags linking peptides to fitness and lifestyle optimization, positioning them as established science rather than experimental compounds.

Does the research actually support peptide safety?

The evidence is much thinner than Fernandes suggests. While some peptides have legitimate research, most studies are small, short-term, or conducted in animals. GHK-Cu has shown wound healing benefits in a few human trials, but the largest involved just 71 patients (Pickart et al., International Wound Journal, 2017).

Ipamorelin research is even more limited. The compound stimulates growth hormone release, but human safety data comes mainly from small pharmacokinetic studies lasting weeks, not years. A 2005 study by Raun et al. in the European Journal of Endocrinology tested ipamorelin in just 32 healthy men for 16 days.

Many popular peptides like BPC-157 have zero published human trials despite widespread underground use.

What did she get wrong about regulation?

Fernandes frames regulatory delays as bureaucratic foot-dragging rather than legitimate safety concerns. But peptides face regulatory scrutiny precisely because long-term safety data doesn't exist. The FDA hasn't approved ipamorelin or most cosmetic peptides for human use.

Her "years of use outside Brazil" claim is misleading. Most peptide use happens in unregulated wellness clinics or through research chemical suppliers. That's not the same as established medical practice.

The fact that something is "studied" doesn't mean it's proven safe or effective for human use. Plenty of compounds look promising in early research but fail in larger trials.

What are the actual risks?

Peptides aren't inherently dangerous, but they're not risk-free either. Injection site reactions, immune responses, and unknown long-term effects are all possible. Growth hormone-releasing peptides like ipamorelin could theoretically increase cancer risk in susceptible individuals.

The bigger issue is quality control. Most peptides come from research chemical companies with no FDA oversight. Purity, contamination, and dosing accuracy vary widely. A 2019 analysis by Cohen et al. in Clinical Toxicology found that 87% of research peptides contained impurities.

Without proper medical supervision, people often use inappropriate doses or combinations. That's where real harm can occur.

What should you actually know?

Some peptides do have legitimate therapeutic potential, but we're still in the early research phase for most compounds. The fact that Silicon Valley biohackers use them doesn't make them proven or safe.

If you're considering peptides, work with a licensed physician who can assess your individual risk factors. Don't trust social media influencers who profit from selling these compounds.

Fernandes isn't entirely wrong that peptides aren't "new" - but old doesn't automatically mean safe or effective. Bloodletting is old too. The question isn't whether peptides have been around, but whether they've been properly tested in humans at the doses people actually use.